Suppr超能文献

静脉铁剂治疗:既往出现不良反应后的再次给药

Intravenous Iron Therapy: Re-administration after Prior Adverse Reaction.

作者信息

Aung Tim, Thein Hla, Aung Sandy Tin, Soe Benjamin Tin Aung, Ohnmar Ei

机构信息

General Practice, The Royal Australian College of General Practitioners, Melbourne, VIC, Australia.

General Practice, Star Medical Centre, Logan, QLD, Australia.

出版信息

Korean J Fam Med. 2023 Nov;44(6):350-354. doi: 10.4082/kjfm.23.0039. Epub 2023 Aug 18.

Abstract

BACKGROUND

Intravenous (IV) iron therapy is performed in community practices and hospitals with modern formulations when oral administration becomes impractical. Effective replacement of iron is important for the treatment of iron deficiency and anemia. Can IV iron be rechallenged in individuals with a history of adverse reactions? This review is to explore the challenge of this, when clinically indicated.

METHODS

After performing a literature search, five studies (combined total sample number=1,006) for re-exposure of IV iron to individuals with a history of past reactions were identified, observed, and analyzed. Re-exposure included reactions ranging from mild to moderate and few cases of severe type.

RESULTS

The majority (>80%) of IV iron rechallenges were tolerable, safe, and successful without major serious incidents. There were no reports of major reactions (severe hypersensitivity reactions or anaphylaxis) in these re-exposures.

CONCLUSION

Re-administration of IV iron therapy in patients with a previous adverse reaction is plausible, with benefit and risk stratification. A rechallenge would depend on the nature and degree of the adverse reaction and use of alternative formulations. Rechallenge to a previous severe hypersensitivity reaction or anaphylaxis with the same product has not been reported in these studies. Evidence on the benefit of premedication use is conflicting and requires further studies.

摘要

背景

当口服补铁不可行时,社区诊所和医院会采用现代制剂进行静脉补铁治疗。有效补充铁剂对缺铁和贫血的治疗至关重要。有不良反应史的个体能否再次接受静脉补铁治疗?本综述旨在探讨在临床有指征时这一问题面临的挑战。

方法

在进行文献检索后,确定、观察并分析了五项关于曾有过不良反应史的个体再次接受静脉补铁治疗的研究(合并样本总数 = 1006)。再次暴露包括从轻度到中度的反应以及少数严重类型的反应。

结果

大多数(>80%)再次接受静脉补铁治疗的情况是可耐受、安全且成功的,未发生重大严重事件。这些再次暴露中未报告有重大反应(严重过敏反应或过敏症)。

结论

既往有不良反应的患者再次接受静脉补铁治疗是可行的,但需要进行获益和风险分层。再次给药取决于不良反应的性质和程度以及替代制剂的使用情况。这些研究中未报告使用同一产品对既往严重过敏反应或过敏症进行再次激发试验的情况。关于预防性用药获益的证据存在矛盾,需要进一步研究。

相似文献

2
Safety of Intravenous Iron Following Infusion Reactions.静脉铁输注后不良反应的安全性。
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1660-1666. doi: 10.1016/j.jaip.2020.11.028. Epub 2020 Nov 26.

本文引用的文献

7
Safety of Intravenous Iron Following Infusion Reactions.静脉铁输注后不良反应的安全性。
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1660-1666. doi: 10.1016/j.jaip.2020.11.028. Epub 2020 Nov 26.
8
World allergy organization anaphylaxis guidance 2020.世界过敏组织2020年过敏反应指南
World Allergy Organ J. 2020 Oct 30;13(10):100472. doi: 10.1016/j.waojou.2020.100472. eCollection 2020 Oct.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验